ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Spending Bill Expected At White House Any Day Now; NIH Awaits 15% Increase.

October 27, 2000

In Brief: Richard Fisher Named Physician-in-Chief, Executive Vice President at Fox Chase Cancer Center

December 7, 2012

Young Investigator Grants Available

July 8, 1977

Retrovirus Vaccination Is Feasible, Workshop Participants Conclude

May 3, 1985

President, Congress, Cancer Letter Take Off

August 22, 1986

Proteomics Promises Ways To Track Response To Therapy

April 25, 2003